Report of Auditors on Financial Results for the quarter and nine months ended December 31, 2025 with UDIN
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.5 pts less than Nifty Microcap 250 and 4.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Pharmaids Pharmaceuticals has submitted the statutory auditors' review reports on its unaudited financial results for the quarter and nine months ended December 31, 2025, under SEBI LODR Regulation 33. The auditor (PPKG & Co., Chartered Accountants) issued a clean (unqualified) review conclusion on both the standalone and consolidated results, stating that nothing came to their attention suggesting any material misstatement or non-compliance with disclosure requirements. The consolidated results include three subsidiaries — Adita Bio Sys Pvt Ltd, Siri Labvivo Diet Pvt Ltd (step-down), and Spring Labs (step-down) — of which two were reviewed by other auditors. Those two subsidiaries reported combined revenues of Rs. 459.71 lakhs (quarter) and Rs. 1,278.49 lakhs (9 months), with net losses of Rs. 46.38 lakhs and Rs. 179.79 lakhs respectively, indicating they are loss-making at the subsidiary level.
This is a routine compliance filing confirming the auditor has signed off on the quarterly numbers without any qualifications or concerns, which is neutral to mildly reassuring for shareholders. The loss-making subsidiaries could weigh on consolidated profitability, but the clean auditor opinion removes a key risk flag for now.